Brief: Novartis AG Discontinues Development Of VHB937 In Amyotrophic Lateral Sclerosis
16/09/2026 17:33
BRIEF-Novartis AG Discontinues Development Of VHB937 In Amyotrophic Lateral Sclerosis Sept 16 (Reuters) - Novartis AG NOVN.S:
NOVARTIS AG: DISCONTINUED DEVELOPMENT OF VHB937 IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) FOLLOWING RESULTS FROM THE PHASE 2 ASTRALS STUDY
NOVARTIS AG: VHB937 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsEurope Research Roundup: Ambu, Intesa Sanpaolo, Solvay
Swiss pharma industry behind in technology and clinical trials, index shows
European shares rise as Democrats take US Congress, Novo Nordisk surges
European shares rise as Democratic sweep lifts clean energy, bank stocks
Europe set to open lower as Democratic sweep fuels AI regulation fears